knowledge -WSS

knowledge

author：focus 2025-09-06 03:50:41 - browse：681

Adam's take main illustration — Molly Ferguson/STAT

Some day-after thoughts on Bristol Myers Squibb acquiring Mirati Therapeutics:

A take-under deal feels meh for biotech sector sentiment.Bristol is paying $58 per share in cash for Mirati, which closed Friday at $60. Granted, Mirati was trading in the $30 range in September, so from there, the roughly 50% premium isn’t terrible. But as Mizuho strategist Jared Holz pointed out, investors would liked to have seen Mirati go for $75-$100 per share.

With the closely watched XBI biotech index down 13% for the year, every M&A deal helps improve sentiment, but this one — maybe just a little. Bristol is paying $4.8 billion in cash to acquire Mirati, or $3.7 billion after accounting for Mirati’s cash. It’s a small bolt-on acquisition for Bristol, which isn’t overpaying.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Zyn nicotine pouches become unlikely player in latest culture war

hotspot

WSS

Can we make enough H5N1 bird flu vaccine if there's a pandemic?

Pancreatic cancer early detection could be helped by AI

Second House panel advances two

Medicare Advantage insurers face 0.2% cut to 2025 payments

Big Tobacco's 'harm reduction': Is it for real, or a sham?

Case highlights the risks of experimental stem cell therapy

hotspot

knowledge

leisure time

Continuity nursing helped my family in our darkest PICU moments

Vertex non

Jerome Adams on the need for new antivirals for Covid

Anxious about a speech? A startup wants you to pop a minty cardiac drug

Dobbs anniversary: the lost opportunity of abortion as health care

Case highlights the risks of experimental stem cell therapy

United colonoscopy coverage change 'may cost lives,' doctors say

Syphilis numbers in the United States reach record heights

Alkermes shareholders re

Readers respond to H5N1 and livestock movements, and more

focus

Philips to halt sales of sleep apnea machines in U.S.

How generative AI ratchets up security threats for health systems

With measles on the rise, a personal story of a devastating disease

Investment in vaccine development is lagging, report finds

10 reasons why health care startups fail

Medicare Advantage insurers face 0.2% cut to 2025 payments

focus

hotspot

focus

hotspot